Skip to Main Content

++

Chapter 64. Emergency Resuscitation Measures

++
++
++

Which of the following statements is true regarding the use of therapeutic hypothermia in patients surviving sudden cardiac death?

++
++
++

A. There is clear evidence to support the use of rapid cooling (ie, within the first 2 hours of cardiac arrest).

++
++

B. The largest randomized trial of therapeutic hypothermia found no benefit of cooling to a goal temperature of 36°C compared to 33°C.

++
++

C. Trials have shown a significant increase in bleeding complications in patients undergoing therapeutic hypothermia.

++
++

D. Current recommendations are that therapeutic hypothermia should be continued for 48 hours followed by gradual rewarming.

++
++

E. All of the above are true.

+
++

The correct answer is B

++
++
++

Current recommendations for the initial management of cardiac arrest patients include which of the following?

++
++
++

A. The use of inspiratory impedance threshold devices if available

++
++

B. High-quality uninterrupted cardiopulmonary resuscitation (CPR) if the initial responders are uncomfortable with mouth-to-mouth resuscitation

++
++

C. After placement of an advanced airway, asynchronous respirations should be provided at a rate of 15 to 20 breaths per minute

++
++

D. Interposed abdominal compression CPR (IAC-CPR) should never be used during the initial management of cardiac arrest patients

++
++

E. There are clear data to support the use of automated chest compression devices instead of conventional CPR

+
++

The correct answer is B

++
++
++

Which of the following causes of sudden cardiac death is the leading cause in the United States?

++
++
++

A. Long QT syndrome

++
++

B. Chronic systolic heart failure

++
++

C. Coronary artery disease

++
++

D. Hypertrophic cardiomyopathy

++
++

E. Congenital heart disease

+
++

The correct answer is C

++
++
++

Which of the following is no longer currently recommended during advanced cardiac life support?

++
++
++

A. Epinephrine every 3 to 5 minutes

++
++

B. Placement of a transvenous pacer for those with asystole

++
++

C. Amiodarone (300 mg bolus) to those with refractory ventricular tachycardia or ventricular fibrillation

++
++

D. Atropine (1 mg) to patients with pulseless electrical activity or asystole

++
++

...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.